CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
United Nations Secretary-General Kofi Annan met this week with executives from nine pharmaceutical companies to encourage them to cut the prices of their anti-HIV drugs and to accelerate research on HIV drugs and diagnostics for children. This was the most recent in a series of U.N. meetings with drugmakers during the last five years. However, it marked the first time that generic-drug manufacturers were included.
Annan said that while the companies have been responding to the world's needs, the epidemic is "still outpacing our efforts, and we need to work together in a broad partnership to step up the response." The executives agreed to review the prices of new and existing HIV diagnostics and antiretroviral medicines toward the goal of making them more affordable and accessible in developing nations. They further pledged to devote more attention to the needs of pediatric HIV patients.
Represented at the meeting were Aspen Phamacare (South Africa), Aurobindo Pharma (India), Bristol-Myers Squibb (U.S.), GlaxoSmithKline (U.K.), Hetero Drugs (India), Johnson & Johnson (U.S.), Merck (U.S.), Ranbaxy Laboratories (India), and Becton, Dickinson and Company's BD Medical unit (U.S.). (Reuters)
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.